Short answer: A compounded BLT cream combining benzocaine 20%, lidocaine 6% and tetracaine 4% delivers triple-local-anaesthetic surface anaesthesia at strengths no single commercial product offers — the commercial EMLA cream carries lidocaine 2.5% and prilocaine 2.5%. The preparation is made as a non-sterile cream for a named patient on a doctor’s prescription under Good Compounding Practice (GCP). Prescribers must flag the methaemoglobinaemia risk from benzocaine at 20%, the cumulative local-anaesthetic load from three agents, and the application-site and area limits that keep systemic absorption within safe bounds.
Why compound a triple-local-anaesthetic cream
Commercial topical anaesthetic products are manufactured to fixed strengths and fixed combinations. EMLA cream — a eutectic mixture of lidocaine 2.5% and prilocaine 2.5% — is the most widely used commercial option for surface anaesthesia on intact skin. A meta-analysis of eutectic mixture of local anaesthetics and amethocaine in paediatrics confirmed the efficacy of this class for procedural pain (Varghese et al., Pediatric Research, 2024; PMID 38429571), and a randomised controlled trial demonstrated efficacy for EMLA in minor surgical procedures (Shaikh et al., Dermatologic Surgery, 2009; PMID 19397664). When a prescriber needs a deeper or more rapid surface anaesthesia than EMLA provides — for procedures involving more sensitive anatomical sites, or for patients who do not achieve adequate anaesthesia with commercial strengths — compounding allows the combination of three local anaesthetics at higher individual concentrations in a single vehicle.
The BLT combination places an ester anaesthetic (benzocaine), a second ester anaesthetic (tetracaine) and an amide anaesthetic (lidocaine) in one preparation. Each acts on voltage-gated sodium channels to block nerve conduction, but they differ in onset time, duration and lipid solubility, which is the rationale for combining them.
Clinical indications and target patients
The BLT cream is typically prescribed for procedural pain on intact skin where commercial EMLA is insufficient: minor dermatological procedures, laser treatments, cosmetic procedures, and needle-related procedures requiring deeper surface anaesthesia. The target patient population is adults or children undergoing brief superficial procedures where topical anaesthesia is appropriate and the prescriber has determined that commercial-strength products do not provide adequate effect.
A study of 10% and 20% benzocaine gels in patients with acute toothache confirmed that 20% benzocaine is used clinically, though the application site in that study was oral mucosa rather than intact skin (Hersh et al., Journal of the American Dental Association, 2013; PMID 23633700). The 20% concentration in the BLT cream is substantially higher than any single-agent commercial benzocaine product for intact skin, which is why the preparation is available only on prescription through compounding.
Dosing and application guidance
The cream is applied as a thin layer to intact skin at the procedure site, typically 30–60 minutes before the procedure, under an occlusive dressing if the prescriber specifies. The amount per application depends on the surface area: a practical guide is approximately 1–2 g per 10 cm² of skin, though the prescriber should specify the exact amount and area. The total dose of all three anaesthetics should be calculated against the patient’s body weight to ensure the cumulative local-anaesthetic load remains within safe limits. For a 70 kg adult, the lidocaine component alone at 6% delivers 60 mg per gram of cream — the maximum recommended lidocaine dose for topical application should not exceed 4.5 mg/kg, which limits application to approximately 5 g of cream for a 70 kg patient on the lidocaine component alone.
Formulation notes
Vehicle and base selection
A pluronic lecithin organogel (PLO) base is commonly selected for the BLT cream because it enhances penetration of lipophilic actives across the stratum corneum. An alternative is an anhydrous cream base, which avoids hydrolysis of the ester anaesthetics (benzocaine and tetracaine). The base must be compatible with both ester and amide chemistry — ester anaesthetics are susceptible to hydrolysis in aqueous environments, which affects stability and BUD.
Stability and beyond-use dating
The beyond-use date (BUD) is typically assigned at 30–90 days for a non-sterile cream, depending on water activity of the base and stability data for the specific combination. An anhydrous base may support a longer BUD by reducing ester hydrolysis. The preparation should be stored at room temperature or refrigerated as specified by the pharmacy, and protected from light.
Compatibility and interactions
Benzocaine and tetracaine are ester-type anaesthetics metabolised by plasma cholinesterases; lidocaine is an amide metabolised by hepatic enzymes. The three actives are pharmaceutically compatible in a single vehicle but the cumulative local-anaesthetic load increases systemic absorption risk. Patients taking Class III antiarrhythmic drugs or with known sensitivity to ester or amide local anaesthetics should be identified before prescribing.
Safety and counselling — methaemoglobinaemia flag
This formulation carries a significant methaemoglobinaemia risk, primarily from benzocaine at 20%. A retrospective review of 28,478 transoesophageal echocardiograms documented benzocaine-induced methaemoglobinaemia with identifiable predisposing factors including age, anaemia and concurrent oxidant medications (Kane et al., Archives of Internal Medicine, 2007; PMID 17923598). A summary of 242 episodes of local-anaesthetic-induced methaemoglobinaemia identified benzocaine as the most common causative agent (Guay, Anesthesia and Analgesia, 2009; PMID 19224791). A randomised study evaluating benzocaine alone and benzocaine plus tetracaine applied to oral mucosa found no methaemoglobin elevations in that setting, but the authors noted that risk depends on dose, application site and patient factors (Wang et al., Clinical Therapeutics, 2017; PMID 28943117).
A study of systemic absorption of topical lidocaine in normal volunteers and patients with post-herpetic neuralgia confirmed that lidocaine is absorbed systemically from topical application, though blood levels remained below toxic thresholds at the doses studied (Campbell et al., Journal of Pharmaceutical Sciences, 2002; PMID 11977110). At 6% lidocaine in the BLT cream, the systemic contribution from the lidocaine component adds to the cumulative anaesthetic load.
Recommended mitigations:
- Apply to intact skin only — never broken, inflamed or mucosal surfaces
- Limit the total application area and calculate the cumulative dose of all three anaesthetics against body weight
- Specify the maximum number of applications per day in the prescription
- Counsel patients on signs of methaemoglobinaemia: cyanosis, dyspnoea, fatigue, headache
- Counsel patients on signs of systemic local-anaesthetic toxicity: dizziness, tinnitus, perioral tingling
- Avoid use in patients with known G6PD deficiency, methaemoglobin reductase deficiency, or concurrent oxidant medications
- Do not apply heat to the treated area — heat increases absorption unpredictably
Documentation checklist for prescribers
- Named patient and prescriber details
- Active ingredients and exact strengths: benzocaine 20%, lidocaine 6%, tetracaine 4%
- Dosage form: cream (specify PLO or anhydrous base preference)
- Clinical rationale: why commercial EMLA is insufficient for this patient
- Application site and area: anatomical location and maximum surface area
- Amount per application and frequency: with calculated cumulative anaesthetic dose per application
- Known sensitivities: ester or amide local-anaesthetic allergies, excipient exclusions
- Safety monitoring plan: methaemoglobinaemia signs, application-area limits
- Review plan: follow-up timing and reassessment triggers
Discussing a BLT cream preparation with Lynnity
Lynnity prepares non-sterile compounded topical anaesthetic creams — including the BLT combination — for named patients on a registered doctor’s prescription, under Good Compounding Practice (GCP). The pharmacy can advise on vehicle selection (PLO versus anhydrous base), excipient compatibility between ester and amide anaesthetics, stability and beyond-use dating for the specific combination, and the cumulative-dose calculation that keeps systemic absorption within safe limits. Where a prescriber is considering a related preparation — for example, a single-agent lidocaine cream at a different strength, or a compounded pain cream incorporating ketamine or amitriptyline for neuropathic pain — the pharmacy can prepare these on prescription as well. The conversation begins with the prescription and formulation brief sent to the pharmacy; the pharmacists can then advise on practicality and any compatibility or stability concerns before proceeding.
Frequently asked questions
What is the methaemoglobinaemia risk with 20% benzocaine in the BLT cream?
Benzocaine is the local anaesthetic most frequently associated with drug-induced methaemoglobinaemia. A review of 242 episodes identified benzocaine as the leading causative agent (Guay, 2009; PMID 19224791), and a retrospective study of 28,478 procedures documented cases with predisposing factors including anaemia and concurrent oxidant medications (Kane et al., 2007; PMID 17923598). The risk is dose- and site-dependent and increases when benzocaine is combined with other local anaesthetics. Prescribers should limit the application area, avoid broken skin, and counsel patients on signs of methaemoglobinaemia.
How does the BLT cream differ from commercial EMLA?
EMLA cream contains lidocaine 2.5% and prilocaine 2.5% — two agents at relatively low concentrations. The BLT cream combines three local anaesthetics at higher individual concentrations: benzocaine 20%, lidocaine 6% and tetracaine 4%. The rationale is deeper surface anaesthesia through multiple agents with different onset and duration profiles. The trade-off is a higher cumulative local-anaesthetic load and a methaemoglobinaemia risk from benzocaine that EMLA does not carry.
What is the maximum safe application area for the BLT cream?
The maximum area depends on body weight and the cumulative dose of all three anaesthetics. The lidocaine component at 6% delivers 60 mg per gram of cream; the maximum recommended lidocaine dose for topical application should not exceed 4.5 mg/kg. For a 70 kg adult, this limits application to approximately 5 g of cream on the lidocaine component alone. The prescriber should calculate the total anaesthetic load and specify the maximum area and frequency in the prescription.
Can the BLT cream be used on children?
Use in children requires careful dose calculation based on body weight, as the cumulative local-anaesthetic load is more significant relative to a smaller body mass. The methaemoglobinaemia risk from benzocaine may be higher in infants and young children. The prescriber should document the clinical rationale, calculate the maximum safe dose for the child’s weight, and specify a conservative application area. This is a prescription-only decision made by the treating clinician.
Reviewed by Vitthia Rama Murti, RPh (RPh 15632).
To discuss a patient-specific BLT cream preparation — or to flag a formulation concern before prescribing — consult Lynnity’s compounding pharmacists, including Lead Pharmacist Vitthia Rama Murti, RPh (RPh 15632), at the compounding facility in MWE Commercial Park, Kepong, Kuala Lumpur.